메뉴 건너뛰기




Volumn 16, Issue 5, 2010, Pages 1355-1357

Does lapatinib work against HER2-negative breast cancers?

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FULVESTRANT; LAPATINIB; LETROZOLE; TAMOXIFEN; TRASTUZUMAB;

EID: 77649125821     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-3223     Document Type: Note
Times cited : (16)

References (12)
  • 1
    • 77649173208 scopus 로고    scopus 로고
    • Lapatinib restores hormone sensitivity with differential effects on ER signaling in cell models of HER2-negative breast cancer with acquired endocrine resistance
    • Leary AF, Drury S, Detre S, et al. Lapatinib restores hormone sensitivity with differential effects on ER signaling in cell models of HER2-negative breast cancer with acquired endocrine resistance. Clin Cancer Res 2010;16:1486-97.
    • (2010) Clin Cancer Res , Issue.16 , pp. 1486-1497
    • Leary, A.F.1    Drury, S.2    Detre, S.3
  • 2
    • 42049121934 scopus 로고    scopus 로고
    • Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance
    • Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008;29:217-33.
    • (2008) Endocr Rev , vol.29 , pp. 217-233
    • Arpino, G.1    Wiechmann, L.2    Osborne, C.K.3    Schiff, R.4
  • 4
    • 33645730357 scopus 로고    scopus 로고
    • Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors
    • Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res 2006;66:3903-11.
    • (2006) Cancer Res , vol.66 , pp. 3903-3911
    • Creighton, C.J.1    Hilger, A.M.2    Murthy, S.3    Rae, J.M.4    Chinnaiyan, A.M.5    El-Ashry, D.6
  • 5
    • 0035476866 scopus 로고    scopus 로고
    • The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: Potential therapy for cancer
    • Rusnak DW, Affleck K, Cockerill SG, et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 2001;61:7196-203.
    • (2001) Cancer Res , vol.61 , pp. 7196-7203
    • Rusnak, D.W.1    Affleck, K.2    Cockerill, S.G.3
  • 6
    • 33750468717 scopus 로고    scopus 로고
    • Reverting estrogen-receptor- negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
    • Munzone E, Curigliano G, Rocca A, et al. Reverting estrogen-receptor- negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Res 2006;8:R4.
    • (2006) Breast Cancer Res , vol.8
    • Munzone, E.1    Curigliano, G.2    Rocca, A.3
  • 7
    • 33646746413 scopus 로고    scopus 로고
    • A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer
    • Xia W, Bacus S, Hegde P, et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A 2006; 103:7795-800.
    • (2006) Proc Natl Acad Sci U S A , vol.103 , pp. 7795-7800
    • Xia, W.1    Bacus, S.2    Hegde, P.3
  • 8
    • 73949105921 scopus 로고    scopus 로고
    • Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM study
    • Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009;27:5529-37.
    • (2009) J Clin Oncol , vol.27 , pp. 5529-5537
    • Kaufman, B.1    Mackey, J.R.2    Clemens, M.R.3
  • 9
    • 41949104971 scopus 로고    scopus 로고
    • Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial
    • Dowsett M, Allred C, Knox J, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 2008;26:1059-65.
    • (2008) J Clin Oncol , vol.26 , pp. 1059-1065
    • Dowsett, M.1    Allred, C.2    Knox, J.3
  • 10
    • 35348877882 scopus 로고    scopus 로고
    • Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy
    • Bartlett JM, Ellis IO, Dowsett M, et al. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. J Clin Oncol 2007;25:4423-30.
    • (2007) J Clin Oncol , vol.25 , pp. 4423-4430
    • Bartlett, J.M.1    Ellis, I.O.2    Dowsett, M.3
  • 11
    • 73149115341 scopus 로고    scopus 로고
    • Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer
    • Johnston S, Pippen J, Jr., Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-46.
    • (2009) J Clin Oncol , vol.27 , pp. 5538-5546
    • Johnston, S.1    Pippen Jr., J.2    Pivot, X.3
  • 12
    • 69849105168 scopus 로고    scopus 로고
    • Progression-free survival (PFS) of patients with HER2-negative, estrogen receptor (ER)-low metastasic breast cancer (MBC) with the addition of lapatinib to letrozole: Biomarker results of EGF30008
    • 45s
    • Finn RS, Press M, Dering J, et al. Progression-free survival (PFS) of patients with HER2-negative, estrogen receptor (ER)-low metastasic breast cancer (MBC) with the addition of lapatinib to letrozole: Biomarker results of EGF30008. Proc Am Soc Clin Oncol 2009;27:45s.
    • (2009) Proc Am Soc Clin Oncol , vol.27
    • Finn, R.S.1    Press, M.2    Dering, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.